



Patent
Attorney's Docket No. 018413-002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of) NON-FEE AMENDMENT
RICHARD J. GREFF, et al.)
Application No.: 08/507,863) Group Art Unit: 1207
Filed: July 27, 1995) Examiner: Unassigned
For: NOVEL COMPOSITIONS FOR)
USE IN EMBOLIZING BLOOD)
VESSELS)

RECEIVED
95 DEC -7 PM 8:32
GROUP 120

PRELIMINARY AMENDMENT TRANSMITTAL LETTER

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Enclosed is a preliminary amendment for the above-identified patent application.

While no fee is believed due with the filing of this preliminary amendment, the Commissioner is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in triplicate.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS

By:

Gerald F. Swiss
Registration No. 30,113

P.O. Box 1404
Alexandria, Virginia 22313-1404
(415) 854-7400

Date: December 1, 1995

Patent
Attorney's Docket No. 018413-002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


In re Patent Application of

RICHARD J. GREFF, et al.

Application No.: 08/507,863

Filed: July 27, 1995

For: NOVEL COMPOSITIONS FOR USE IN
EMBOLIZING BLOOD VESSELS



NON-FEE AMENDMENT

Group Art Unit: 1207

Examiner: Unassigned

4/a
D. Cassaway
12-20-95
95 DEC -7 PM 8:32
REC'D U.S. PTM
1207

PRELIMINARY AMENDMENT

The Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Prior to examination of the above-noted application on the merits, entry of the following amendments is earnestly solicited.

In the Specification:

At page 9, line 6, after "in vivo" insert --use--.

At page 15, line 29, after "No.", delete " " and insert in place thereof
--08/508,248--

In the Claims:

Amend Claims 1-6 as follows:

--1. (amended) A [An embolizing] composition comprising:

(a) from about 2.5 to about 8.0 weight percent of an ethylene vinyl alcohol copolymer [embolizing agent];

(b) from about 10 to about 40 weight percent of a water insoluble contrast agent selected from the group consisting of tantalum, tantalum oxide and barium sulfate;

(c) from about 52 to about 87.5 weight percent of a biocompatible solvent